Specialism 'inevitable' for some pharma companies, says Novo Nordisk CSO
This article was originally published in Scrip
Executive Summary
It may come as a surprise to some, but Mads Krogsgaard Thomsen, executive vice-president and long-serving CSO of Novo Nordisk, believes the defining characteristic of his company is not its expertise in diabetes, despite Novo Nordisk supplying more than half of the world's insulin.